Electrocardiogram Monitoring Practices for Hospitalized Adults Receiving Antipsychotics: A Retrospective Cohort Study.


Journal

Journal of psychiatric practice
ISSN: 1538-1145
Titre abrégé: J Psychiatr Pract
Pays: United States
ID NLM: 100901141

Informations de publication

Date de publication:
03 Mar 2022
Historique:
entrez: 3 3 2022
pubmed: 4 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

Antipsychotics are frequently used for managing both acute and chronic neuropsychiatric disorders. While antipsychotics are known to be associated with increased mortality due to cardiac arrhythmia, there is a lack of consensus on the timing and frequency of electrocardiogram (ECG) monitoring.  The goal of this study was to examine current ECG monitoring practices for adults receiving antipsychotics, specifically during hospital admission. The study involved a multisite retrospective chart review of adults admitted across 8 hospitals between January 2010 and December 2015 who received antipsychotics during hospitalization. The primary outcome was the presence of an ECG after receiving an antipsychotic. During the study period, there were 26,353 hospitalizations during which adults received antipsychotic medication; the average age of the patients was 61.4 years, 50.1% were female, and 64.8% were white. The average comorbidity score was 1.4 with a median length of stay of 8.3 days. Of the 26,353 patients who were hospitalized, 60.6% (n=15,977) of patients in the sample had an ECG during their hospitalization, and 41.2% (n=10,865) had the ECG following antipsychotic administration. Patients who received a follow-up ECG had a longer length of stay (median: 11.3 d) compared with those who did not receive a follow-up ECG (median: 7.0 d). Follow-up ECGs were more likely among patients who had a history of heart failure [odds ratio (OR)=1.17, 95% confidence interval (CI): 1.06-1.30, P=0.002], who were receiving multiple antipsychotics (OR=1.3, 95% CI: 1.24-1.36, P<0.001) or other QT-prolonging medications (OR=1.09, 95% CI: 1.07-1.1, P<0.001), who were receiving risperidone (OR=1.12, 95% CI: 1.004-1.25, P=0.04), and who showed an increase in QTc duration (OR per 10 ms increase=1.02, 95% CI: 1.01-1.04, P=0.003). Follow-up ECGs were less likely to be administered to patients who were receiving antipsychotics before admission (OR=0.93, 95% CI: 0.87-0.997, P=0.04). This study demonstrated that, in a large health system, ECG monitoring is not routinely practiced for hospitalized patients receiving antipsychotics. Further studies are needed to identify patients who would most benefit from ECG monitoring in the acute care setting.

Identifiants

pubmed: 35238822
doi: 10.1097/PRA.0000000000000613
pii: 00131746-202203000-00004
doi:

Substances chimiques

Antipsychotic Agents 0
Risperidone L6UH7ZF8HC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-116

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76:1346–1353.
Gallagher P, Curtin D, de Siún A, et al. Antipsychotic prescription amongst hospitalized patients with dementia. QJM. 2016;109:589–593.
Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics. J Psychiatr Pract. 2014;20:196–206.
Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–487.
Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169:900–906.
Centers for Medicare and Medicaid Services (CMS). Atypical antipsychotic medications: use in adults. Woodlawn, MD: CMS; 2015. Available at: www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-adult-factsheet11-14.pdf . Accessed December 27, 2021.
US Food and Drug Administration (FDA). Atypical Antipsychotic Drugs Information: Drug Safety Information for Patients and Providers. Silver Spring, MD: FDA; 2016. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/atypicalantipsychotic-drugs-information . Accessed December 27, 2021.
Drew BJ, Califf RM, Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young. Circulation. 2004;110:2721–2746.
American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Washington, DC: American Psychiatric Association; 2006.
De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199:99–105.
Lambiase PD, De Bono JP, Schilling RJ, et al. British Heart Rhythm Society clinical practice guidelines on the management of patients developing QT prolongation on antipsychotic medication. Arrhythmia Electrophysiol Rev. 2019;8:161–165.
Funk MC, Beach SR, Bostwick JR, et al. QTc prolongation and psychotropic medications. Am J Psychiatry. 2020;177:273–274.
Sandau KE, Funk M, Auerbach A, et al. Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. Circulation. 2017;136:e273–e344.
Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39:16–25.
Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016;10:1–9.
Preskorn SH. Patient with bipolar disorder and familial QT prolongation: what to do? J Psychiatr Pract. 2006;12:109–112.
Preskorn SH. Complexities of personalized medicine. J Psychiatr Pract. 2013;19:397–405.
Preskorn SH, Lochmann DB, Sohail Z. QTc, the multitude of ways it is calculated and implications for clinical practice: a case example. J Psychiatr Pract. 2021;27:43–47.

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH